Tectonic Advisors LLC Acquires 280 Shares of Encompass Health Co. (NYSE:EHC)

Tectonic Advisors LLC increased its position in Encompass Health Co. (NYSE:EHC) by 4.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,336 shares of the company’s stock after acquiring an additional 280 shares during the quarter. Tectonic Advisors LLC’s holdings in Encompass Health were worth $612,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of EHC. UMB Bank n.a. raised its holdings in Encompass Health by 387.7% in the 3rd quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after acquiring an additional 252 shares during the period. V Square Quantitative Management LLC raised its holdings in Encompass Health by 53.0% in the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock worth $39,000 after acquiring an additional 140 shares during the period. Oakworth Capital Inc. bought a new position in Encompass Health in the 2nd quarter worth $40,000. Benjamin F. Edwards & Company Inc. raised its holdings in Encompass Health by 58.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company’s stock worth $46,000 after acquiring an additional 198 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Encompass Health in the 2nd quarter worth $58,000. Institutional investors own 97.25% of the company’s stock.

Encompass Health Price Performance

NYSE:EHC opened at $93.46 on Friday. The firm has a market cap of $9.40 billion, a PE ratio of 23.84, a price-to-earnings-growth ratio of 1.45 and a beta of 0.88. Encompass Health Co. has a 12 month low of $57.55 and a 12 month high of $98.74. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 1.08. The company’s 50-day moving average price is $93.58 and its two-hundred day moving average price is $88.22.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Monday, August 5th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.10. Encompass Health had a net margin of 7.88% and a return on equity of 17.83%. The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.30 billion. During the same period in the previous year, the business earned $0.95 earnings per share. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. On average, equities analysts anticipate that Encompass Health Co. will post 4.18 EPS for the current fiscal year.

Encompass Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Thursday, January 2nd will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date of this dividend is Thursday, January 2nd. Encompass Health’s dividend payout ratio is presently 17.35%.

Encompass Health announced that its board has authorized a share buyback program on Wednesday, July 24th that allows the company to buyback $500.00 million in shares. This buyback authorization allows the company to purchase up to 5.4% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

Several research firms have issued reports on EHC. Barclays decreased their price target on shares of Encompass Health from $113.00 to $109.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Leerink Partners began coverage on shares of Encompass Health in a research report on Wednesday, July 10th. They issued an “outperform” rating and a $100.00 price target on the stock. Royal Bank of Canada raised their price target on shares of Encompass Health from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, September 26th. KeyCorp began coverage on shares of Encompass Health in a research report on Friday, October 11th. They set an “overweight” rating and a $115.00 target price on the stock. Finally, Truist Financial lifted their target price on shares of Encompass Health from $104.00 to $108.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Eight investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $104.67.

Insiders Place Their Bets

In other Encompass Health news, CFO Douglas E. Coltharp sold 12,260 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $86.34, for a total value of $1,058,528.40. Following the completion of the transaction, the chief financial officer now directly owns 136,227 shares of the company’s stock, valued at approximately $11,761,839.18. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 2.10% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.